Rate My Professor Peter Vanburen

Peter VanBuren, M.D., is an Associate Professor of Medicine in the Division of Cardiovascular Medicine and an Associate Professor of Molecular Physiology and Biophysics at the University of Vermont Larner College of Medicine. He serves as Director of the Cardiovascular Care Unit and Director of the Heart Failure Program at the University of Vermont Medical Center. VanBuren received his M.D. from the University of Vermont College of Medicine. He completed his residency in Internal Medicine at Georgetown University and his fellowship in Cardiology at the University of Vermont Medical Center. Earlier in his career, he conducted postdoctoral research as an associate in the Warshaw Laboratory at the University of Vermont from 1992 to 1994. He is board-certified in heart failure and specializes in echocardiography and advanced heart failure management. VanBuren is actively involved in the clinical education of medical students, residents, and fellows at the University of Vermont.

VanBuren's research delineates the role of sarcomeric proteins in the contractile deficit of human myocardial failure, utilizing human myocardial biopsy samples and in vitro models of muscle contraction to identify molecular defects in the contractile machinery. These findings inform therapies targeting maladapted myocardial signaling pathways to improve survival in heart failure patients. As local principal investigator, he participates in multi-center clinical trials to enhance heart failure care. His publications include 'Transcatheter treatment of dual aortic-mitral pathology using transcatheter aortic valve replacement and transcatheter mitral edge-to-edge repair' (2025, Cardiovasc Revasc Med), 'Congenital left ventricular wall defects presenting with ventricular arrhythmias: A case series' (2020, HeartRhythm Case Rep), 'Beta-Blocker Cessation in Stable Outpatients With Heart Failure With a Preserved Ejection Fraction' (2020, J Card Fail), 'Pro-Inflammatory Biomarkers in Stable Versus Acutely Decompensated Heart Failure With Preserved Ejection Fraction' (2018, J Am Heart Assoc), 'Abundance, localization, and functional correlates of the advanced glycation end-product carboxymethyl lysine in human myocardium' (2017, Physiol Rep), 'Nitrate's effect on activity tolerance in heart failure with preserved ejection fraction trial: rationale and design' (2015, Circ Heart Fail), 'Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial' (2013, JAMA), 'Sarcomeric Proteins in Hypertrophied and Failing Myocardium: An Overview' (2005, Heart Fail Rev), 'Cooperative Activation of the Cardiac Myofilament: The Pivotal Role of Tropomyosin' (2010, Circulation), and 'A Combined Immunoelectron Microscopic and Stereologic Method to Detect Advanced Glycation End-Products in Human Myocardium' (2010, Histochem Cell Biol).